Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Advisory Panel Narrowly Recommends Genzyme HoFH Drug
FDAnews Drug Daily Bulletin
Oct. 22, 2012 | Vol. 9 No. 207
FDA Advisory Panel Narrowly Recommends Genzyme HoFH Drug
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9–6 Thursday to recommend approval of Genzyme and Isis Pharmaceuticals’ homozygous familial hypercholesterolemia (HoFH) drug Kynamro. The vote comes one day after the panel recommended approval of Aegerion’s HoFH treatment by a wider margin. As with Aegerion’s lomitapide, EMDAC panelists expressed numerous concerns over Kynamro’s (mipomersen) safety profile.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.